In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX), with a price target of $31. The company’s shares opened today at $31.35.
Rivkind Koffler noted:
“We switched from Symphony Health data last month, after a sizeable data restatement from the vendor rendered our prior estimates unreliable.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 12.8% and a 47.3% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Adamas Pharmaceuticals, and Jazz Pharmaceuticals.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $45.67, a 45.7% upside from current levels. In a report issued on June 21, BMO Capital also maintained a Hold rating on the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $51.10 and a one-year low of $26.95. Currently, Pacira Pharmaceuticals has an average volume of 932.7K.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
